Suryaa International Desk: Tumors shrink in 69 percent of patients! Surya Health & Science Bureau: Towards providing a new treatment for prostate cancer that becomes fatal in men... Tumors shrank in 69 percent of patients! Surya Health & Science Bureau: International pharma giant 'Johnson and Johnson' (J&J) has registered a major milestone towards providing a new treatment for prostate cancer, which turns fatal in men. The company has announced that its experimental oral drug 'JNJ-6143' has shown promising results in early clinical trials.
In advanced stage prostate cancer patients, the drug not only significantly reduced the size of tumors but also showed complete cure in some cases. The research findings were presented at the European Society for Medical Oncology (ESMO) conference. Revolutionary results in clinical trials: This experiment was carried out with a dose of 50 milligrams on advanced stage prostate cancer patients who had previously failed multiple treatments: Shrunk of Tumors: Medical tests confirmed that 69 percent of patients with measurable cancerous tumors showed significant shrinkage or complete removal of tumors. PSA Decrease: In 77 percent of patients with measurable prostate cancer, the PSA blood test showed a decrease of more than 50 percent, and 48 percent of patients recorded a decrease of more than 90 percent. Decreased.
New treatment method – 'Riptac' technology: Unlike conventional cancer drugs, this drug uses a new technology (RIPTAC platform) that destroys the balance of proteins necessary for cancer cells to survive and destroys only cancer cells without harming healthy cells. Johnson & Johnson acquired the rights to the treatment last year by acquiring Halda Therapeutics for $3.05 billion. The researchers said that only minor side effects such as nausea and cholesterol increase were seen in the patients, and the next phase of trials will be started to test it on a larger scale of patients.